A federal panel advising the FDA narrowly backed a move linked to Robert F. Kennedy Jr.'s peptide push, voting 8-6 to recommend easier access to several peptide substances. The result gives momentum to products that have gained attention among wellness influencers and celebrities.
The recommendation came despite clear resistance from agency scientists. According to the panel discussion, government experts warned that some of the peptide chemicals under review do not have enough evidence showing they are safe or effective.
That split highlights a growing clash between consumer demand for wellness-related compounds and the standards regulators use to evaluate medical products. Supporters of broader access see peptides as increasingly popular and sought after, while critics argue popularity is not the same as proof.
Because the vote was close, the outcome is likely to keep debate alive over how the FDA should handle peptides that are widely promoted but still face scientific questions. For now, the advisory panel's decision signals support for easing access, even as concerns from federal scientists remain unresolved.
